^
Association details:
Evidence:
Evidence Level:
Sensitive: C4 – Case Studies
Title:

First report of furmonertinib as a first-line treatment in advanced lung adenocarcinoma patients harboring EGFR exon 20 insertion mutations after the kinase domain αC-helix: Two case reports and a literature review

Published date:
12/29/2023
Excerpt:
The second case included a 40-year-old male who had an EGFR ex20ins mutation (p.N771_P772insVal). He had a good response to furmonertinib and exhibited stable disease according to response evaluation criteria in solid tumors with a progression-free survival of 10.90 months.
DOI:
10.1097/MD.0000000000036667